People · Operator
Named in public records as an officer, director or promoter · active 2009–2012 · Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Xanodyne Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $131.6M | $3.1B | 2009 |
| Aratana Therapeutics, Inc. | — | Pharmaceuticals | Series B | $67.3M | $1.0B | 2010 |
| Rhythm Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $60.0M | $765.1M | 2010 |
| Pharmathene, Inc | — | Other | Series B | $29.2M | $164.4M | 2009 |
Steven St. Peter at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steven St. Peter on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Craig Tooman | 2 | 3 |
| Edward Mathers | 1 | 12 |
| Todd Foley | 1 | 12 |
| David Rosen | 1 | 10 |
| John Pappajohn | 1 | 10 |
| Jay Lichter | 1 | 7 |
| Jay Lichter, Ph.D. | 1 | 5 |
| Dennis Purcell | 1 | 5 |
| Ron Meeusen | 1 | 4 |
| Derace L Schaffer | 1 | 4 |
| Robert Gerber | 1 | 4 |
| Keith Gottesdiener | 1 | 4 |
| Lou Tartaglia | 1 | 3 |
| Vaughn M. Kailian | 1 | 3 |
| Eric I. Richman | 1 | 3 |
| Michael Valentino | 1 | 3 |
| Jeffrey W. Runge | 1 | 3 |
| Bart Henderson | 1 | 3 |
| Stephen A Stamp | 1 | 3 |
| Linda Rhodes | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.